The company’s proprietary molecules labeled with the radioactive isotope of fluorine combined with PET scanning provide non-invasive, highly specific and efficient assessment of heart metabolism and physiology. FluoroPharma’s cardiovascular program targets the historically largest potential market of nuclear medicine.
Molecular imaging fulfills numerous unmet needs in diagnosis by enabling visualization, characterization and measurement of biological processes at the molecular and cellular level. Unlike traditional imaging modalities – MRI, CT, and Ultrasound – that reveal the anatomical manifestation of disease, PET provides insight into physiology and can detect disease before anatomical manifestation is identified. The market for molecular imaging agents currently exceeds $1.7 billion annually and promises rapid growth for the foreseeable future.
FluoroPharma’s comprehensive technology platform was developed by scientists at the Massachusetts General Hospital. To date, the company has been issued four US patents and has seven applications pending in addition to strong international protection. With a highly competent management team in place and the necessary resources to advance clinical development, FluoroPharma is well positioned to capitalize on its superior imaging technology.
Key Investment Highlights
• Clinical Trials Confirmed Technologies are Safe and are Now Proving They Are Effective
• Intellectual Property in Place to Protect Proprietary Innovations Around the World
• Strong Cash Position to Accelerate Business Strategy
• Technology Targets Multiple, Multimillion Dollar Healthcare Markets With Strong Unmet Medical Needs
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
